酿酒酵母
细胞外小泡
核糖核酸
细胞外
药物输送
小泡
化学
生物化学
细胞生物学
生物
酵母
基因
有机化学
膜
作者
Meng Yuan,Wenyuan Ma,Bingxin Liu,Xue Zou,Bilian Huang,Xiaoyan Tian,Jin Yu,Nan Zheng,Zhiwei Wu,Yongxiang Wang
标识
DOI:10.1016/j.xphs.2024.10.035
摘要
Employing small extracellular vesicles (EVs) as drug delivery vehicles presents a plethora of advantages over conventional drug delivery methods, including biological compatibility, engineering versatility for targeted delivery, and biodegradability. Therefore, strategies aimed at amplifying their therapeutic potential involve developing efficient, tissue-specific, and non-immunogenic delivery approaches. Despite rapid advancements in the realm of EVs as drug delivery systems in recent years, the availability of a high-yield, reproducible, and cost-effective source for EVs production and isolation remains a limiting factor for practical application. In this study, we isolated EVs from Saccharomyces cerevisiae (S.c) and loaded them with cargoes such as hsa-miR-143 (an apoptosis-inducing miRNA) or miR-H6 (a miRNA targeting HSV-1). We demonstrated the capability of these EVs to deliver microRNAs or even large mRNA to a variety of cell types. The therapeutic potential of S.c-derived EVs (S.c-EVs) was further evidenced by their ability to inhibit tumor growth in animal models. The S.c-EVs proved to be safe and non-immunogenic in vivo. Our results suggest that Saccharomyces cerevisiae represents a cost-effective source of extracellular vesicles, serving as nanocarriers for functional drug delivery in therapeutic applications.
科研通智能强力驱动
Strongly Powered by AbleSci AI